PMID: 8451782Feb 1, 1993Paper

Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis

Therapeutic Drug Monitoring
D J TouwW Bakker

Abstract

The predictive performance of a dosage calculation method for the optimization of tobramycin therapy was studied retrospectively in 29 patients with cystic fibrosis. The dosage calculation method was based on a linear one-compartment open model. It used peak and trough serum concentrations of the aminoglycoside. Bias in the peak concentration was 0.20 mg/L and precision was 1.2 mg/L. Bias in the trough concentration was -0.06 mg/L and precision was 0.33 mg/L. The results were clinically satisfactory. Comparison with previously published results of the predictive performance of other dosage calculation methods showed that the method studied was at least as good.

Citations

Jun 1, 1995·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·G Wu
Dec 10, 1999·Journal of Clinical Pharmacology·L P JamesE A Argao
Aug 19, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·A P PrayleA R Smyth
Nov 4, 2020·Antimicrobial Agents and Chemotherapy·Tara GallagherKatrine L Whiteson
Jan 1, 1997·Antimicrobial Agents and Chemotherapy·D J TouwD D Briemer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.